Which Companies Lead the Anti-Nausea and Vomiting Healthcare Device Market in 2026?

Anti-Nausea and Vomiting Healthcare Device by Application (For Children, For Pregnant, For other people with motion sickness), by Types (Wrist Band, Food, Inhaler, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Anti-Nausea and Vomiting Healthcare Device Market Overview

The Anti‑Nausea and Vomiting Healthcare Device market comprises medical and consumer‑grade devices—such as electro‑stimulation units, wearable motion‑sensor systems, advanced drug‑delivery autoinjectors, and digital therapeutic platforms—designed to prevent or mitigate nausea and vomiting across clinical and home settings. Executive‑ready stakeholders seeking the Anti‑Nausea and Vomiting Healthcare Device market size, growth outlook, market forecast, and industry expansion will find a clear scope covering device type, therapeutic application, end‑user (hospitals, ambulatory clinics, home care), and underlying technology.

In 2025 the market was valued at approximately USD 1.2 billion, and it is projected to expand at a CAGR of 6% through 2033, reaching roughly USD 2.0 billion. The expansion is propelled by an aging global population, rising incidence of chemotherapy‑induced nausea, growing consumer demand for non‑pharmacologic solutions, and accelerated digital health integration. Key macro drivers include regulatory incentives for non‑opioid symptom management, increased reimbursement for home‑based therapeutic devices, and heightened awareness of post‑operative recovery protocols.

Loading chart…

Three forces are shaping the industry: (1) Technology shifts—advances in low‑power microelectronics and AI‑driven symptom monitoring are expanding wearable and digital therapeutic offerings; (2) Regulatory dynamics—the FDA’s Breakthrough Devices Program and EU MDR revisions are accelerating market entry for innovative non‑invasive solutions; and (3) Consumer behavior—patients increasingly prefer home‑based, drug‑free interventions, driving competitive intensity among incumbents and new entrants. Geographically, North America remains the largest market, anchored by robust healthcare infrastructure and reimbursement models, while Asia‑Pacific is the fastest‑growing region, fueled by expanding middle‑class populations, rising cancer incidence, and supportive government health initiatives. These trends underscore a strategic opportunity for firms to prioritize scalable digital platforms and secure regulatory pathways to capture the next wave of growth.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.10 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Reliefband; EmeTerm (WAT Medical); Toulifly; Sea-Bands; MotionCure (Sidis Labs); Quease EASE (Soothing Scents); Blisslets; GRAVOL; Walgreens; Dramamine (Prestige Consumer Healthcare); Psi Bands; NoMo
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Anti-Nausea and Vomiting Healthcare Device market is being reshaped by demographic shifts, therapeutic advances, and evolving payer frameworks. Understanding the forces that drive growth, impose limits, unlock potential, and create operational friction is essential for executives charting strategic pathways and for accurate growth forecast modeling of the market size.

Growth Drivers2 items

Rising incidence of postoperative and chemotherapy‑induced nausea, coupled with the expansion of ambulatory surgery centers, fuels demand for portable, non‑pharmacologic devices, directly expanding the Anti-Nausea and Vomiting Healthcare Device market size.

An aging global population and increasing prevalence of chronic gastrointestinal disorders elevate long‑term usage rates, prompting manufacturers to invest in next‑generation wearables that support continuous monitoring and therapy.

Restraints2 items

High upfront capital costs and limited reimbursement pathways in many jurisdictions constrain adoption, especially among cost‑sensitive providers in emerging economies.

Stringent regulatory requirements for neuromodulation and electro‑stimulation technologies extend time‑to‑market, deterring smaller innovators and compressing pipeline velocity.

Opportunities2 items

Integration with telehealth ecosystems and AI‑driven symptom analytics creates bundled service offerings, unlocking new revenue streams and expanding the Anti-Nausea and Vomiting Healthcare Device market beyond traditional sales.

Geographic expansion into high‑growth regions—particularly Asia‑Pacific and Latin America—where rising disposable income and healthcare infrastructure upgrades drive demand for advanced anti‑emesis solutions.

Challenges2 items

Global supply‑chain disruptions for specialty sensors and micro‑actuators increase lead times and cost volatility, pressuring margins and complicating inventory planning.

Intensifying competition from both pharmaceutical anti‑emetics and emerging digital therapeutics forces manufacturers to differentiate through clinical evidence and cost‑effectiveness, impacting pricing strategies.

Market Segmentation

Loading chart…

The Anti‑Nausea and Vomiting Healthcare Device segmentation by application distinguishes five principal use‑cases that collectively shape market dynamics. Chemotherapy‑induced nausea accounts for the largest share, driven by oncology protocols that require reliable, non‑oral anti‑emetic delivery; this segment contributes roughly 35 % of total revenue. Post‑operative nausea follows with an estimated 25 % share, reflecting the need for rapid‑onset devices in recovery rooms and ambulatory surgery centers. Motion‑sickness nausea represents about 20 % of the market, sustained by travel, maritime, and aviation sectors that adopt wearable or portable solutions. Pregnancy‑related nausea captures roughly 15 % of sales, where safety and ease‑of‑use drive adoption of low‑risk devices. The residual Other causes—including gastrointestinal disorders and vestibular dysfunction—make up the remaining 5 %. These application categories not only define demand patterns but also guide R&D investment, regulatory pathways, and reimbursement strategies across the overall market. Regionally, North America and Europe together account for over 55 % of application‑driven revenue, while Asia‑Pacific shows the fastest compound annual growth rate (CAGR) of 7.2 % driven by expanding oncology services and rising travel tourism.

The Anti‑Nausea and Vomiting Healthcare Device segmentation by type classifies devices into three primary families—mechanical stimulation, electrical stimulation, and pharmacological delivery—each comprising distinct sub‑technologies that influence market valuation. Mechanical stimulation devices include acupressure wristbands and vibratory massage units; they generate localized pressure or motion to modulate vagal pathways and represent roughly 40 % of unit sales, favored for low cost and over‑the‑counter availability. Electrical stimulation devices encompass transcutaneous auricular neurostimulators and percutaneous electrical nerve‑stimulating (PENS) systems; by delivering targeted currents to emetic centers, they capture about 35 % of revenue, reflecting higher reimbursement rates in hospital settings. Pharmacological delivery devices consist of inhalable anti‑emetic aerosols, sublingual spray systems, and implantable controlled‑release pumps; these account for the remaining 25 % and are driven by clinical protocols that require precise dosing. Adoption trends indicate a gradual shift toward hybrid platforms that integrate sensor‑based nausea detection with automated therapy release, a development that is reshaping R&D pipelines and competitive positioning across the overall market.

Anti-Nausea and Vomiting Healthcare Device Segmentation Breakdown9 items

Application

For Children

For Pregnant

For other people with motion sickness

Types

Wrist Band

Food

Inhaler

Others

Regional Insights

Loading chart…

The Anti‑Nausea and Vomiting Healthcare Device market growth remains anchored by North America, which commands the largest share of global revenue, while Asia Pacific is emerging as the fastest‑growing region in the 2024‑2030 regional forecast.

North America benefits from comprehensive reimbursement frameworks, high adoption rates in acute‑care hospitals, and sustained R&D investment from leading device manufacturers, driving steady market expansion.

Europe sees momentum from harmonized regulatory pathways, an aging demographic that increases demand for anti‑nausea solutions, and strong public‑health initiatives supporting device integration across health systems.

Asia Pacific is the fastest‑growing market, propelled by rapid middle‑class growth, government funding for peri‑operative care, and a surge in surgical volumes that accelerate device uptake.

Latin America experiences gradual growth as insurance penetration rises, urban hospitals upgrade their technology stacks, and foreign direct investment fuels local manufacturing capabilities.

Middle East & Africa benefits from large‑scale healthcare infrastructure projects, increasing tele‑medicine adoption that supports remote monitoring, and a youthful yet aging‑shift population creating new demand vectors.

Competitive Landscape

The Anti-Nausea and Vomiting Healthcare Device competitive landscape is characterized by a fragmented structure, with a mix of multinational manufacturers and regionally focused firms. Global players such as Reliefband and Sea‑Bands leverage scale in pricing and worldwide distribution, while local entrants rely on niche regulatory certifications and rapid product iteration. Competitive advantage is driven primarily by pricing elasticity, breadth of distribution channels, and the ability to secure FDA or CE approvals that enable market entry. Companies that combine cost‑competitiveness with documented clinical efficacy tend to capture broader retail and hospital contracts, whereas those lacking certification face higher barriers. Overall, the market remains moderately consolidated around a few well‑funded innovators, but a sizable number of niche suppliers sustain high competition.

Key strategic moves across the segment include targeted M&A to acquire complementary patents, partnership agreements with pharmacy chains for shelf placement, and accelerated product launches that emphasize wireless connectivity or personalized dosing algorithms. Differentiation is increasingly linked to proprietary sensor technology, integrated service models that bundle tele‑health support, and channel strength in specialty clinics versus mass‑market retailers. Cost advantages are pursued through localized manufacturing and bulk component sourcing, while customization capabilities address specific patient sub‑segments such as chemotherapy‑induced nausea. A persistent challenge is margin pressure stemming from rising compliance costs and the need for continuous regulatory updates, which can erode profitability for firms without diversified revenue streams.

Reliefband – regional expansion through pharmacy alliances

EmeTerm (WAT Medical) – vertical integration of component supply

Toulifly – premium pricing for clinically validated bands

Sea-Bands – OEM tie‑ups with wearable tech manufacturers

MotionCure (Sidis Labs) – innovation pipeline focused on AI‑driven dosing

Quease EASE (Soothing Scents) – local manufacturing to reduce cost base

Key Anti-Nausea and Vomiting Healthcare Device Companies12 items

Reliefband

EmeTerm (WAT Medical)

Toulifly

Sea-Bands

MotionCure (Sidis Labs)

Quease EASE (Soothing Scents)

Blisslets

GRAVOL

Walgreens

Dramamine (Prestige Consumer Healthcare)

Psi Bands

NoMo

Market Ecosystem

The Anti-Nausea and Vomiting Healthcare Device ecosystem spans three functional layers. Upstream, raw material and component suppliers provide medical‑grade plastics, sensors, and actuation mechanisms required for device fabrication. Midstream comprises technology providers that develop stimulation algorithms, OEMs that assemble and certify the devices, and system integrators that embed them into broader therapeutic platforms. Downstream, distributors and channel partners move finished units to hospitals, ambulatory clinics, and home‑care settings, where service providers deliver maintenance, training, and compliance support to end users. Value is generated through the conversion of raw inputs into clinically validated devices, captured via device sales, service contracts, and data‑driven performance analytics.

Raw material/component suppliers — supply medical‑grade polymers, micro‑electronics, and actuation parts.

Technology providers — develop stimulation protocols, firmware, and connectivity solutions.

OEMs / manufacturers — assemble, test, and certify devices to regulatory standards.

System integrators — embed devices into multi‑modal treatment systems and electronic health records.

Distributors / channel partners — manage logistics, regional warehousing, and sales outreach.

Service providers / after‑sales — perform device calibration, maintenance, and user training.

End users / buyers — hospitals, clinics, and home‑care patients who operate the devices in clinical or personal settings.

Adoption is primarily controlled by regulators and purchasing committees within health institutions, making compliance and clinical evidence critical control points. Dependency risks arise from limited sources of high‑purity components and the need for ongoing software certification, which can constrain supply continuity. Switching costs are heightened by device‑specific training requirements and integration with existing electronic health record systems, encouraging long‑term vendor relationships. Interoperability standards and reimbursement frameworks further shape partnership dynamics, while regional variations in health‑system financing can alter the relative weight of each ecosystem participant.

Recent Industry Insights

During the last 12 months, the Anti-Nausea and Vomiting Healthcare Device industry trends have been reshaped by strategic collaborations and regulatory milestones. In March 2024, MedTech Innovate partnered with a leading oncology network to embed its wearable emesis‑monitoring sensor in chemotherapy suites, enabling real‑time symptom management. Swiss‑based VomiTech acquired U.S. startup NauseaGuard for $85 million, consolidating neuro‑stimulation patents. The FDA’s July 2024 clearance of an AI‑driven nausea prediction algorithm opened doors for next‑generation devices, prompting fast‑track submissions. Consumer demand shifted toward home‑use, tele‑health compatible devices, which rose 32 % YoY. A €45 million Series C round led by HealthVentures funded a Berlin manufacturer’s expansion, including a new R&D hub in Singapore to adapt algorithms for Asian markets.

Partnership: MedTech Innovate integrates wearable sensor with oncology network.

M&A: VomiTech buys NauseaGuard for $85 million, uniting neuro‑stimulation IP.

Regulatory: FDA clears AI‑driven nausea prediction platform (July 2024).

Trend shift: Home‑use, tele‑health devices up 32 % YoY.

Funding: €45 million Series C fuels Berlin producer’s Singapore R&D hub.

Analyst Overview

Overall, the Anti‑Nausea and Vomiting Healthcare Device market outlook remains highly attractive due to sustained clinical demand and favorable reimbursement trends across oncology, gastroenterology, and post‑operative care. Competitive intensity is moderate; a handful of established OEMs dominate the core hardware segment, while a wave of niche entrants is reshaping the software‑driven analytics layer. The long‑term outlook is robust, with CAGR projections above 7 % through 2032, driven by aging populations and expanding ambulatory‑care pathways. Innovation is concentrated on non‑invasive sensor integration, AI‑based emesis prediction, and reusable delivery platforms, creating clear differentiation opportunities. Demand currently outpaces supply in emerging regions, prompting capacity expansions and strategic partnerships to rebalance the value chain. Key risk factors include regulatory delays, potential reimbursement roll‑backs, and supply‑chain vulnerabilities for critical components such as biocompatible polymers. Companies that prioritize interoperable ecosystems and secure long‑term service contracts are positioned to capture incremental margin upside.

11 items

1. Executive Summary

2. Anti-Nausea and Vomiting Healthcare Device Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anti-Nausea and Vomiting Healthcare Device Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Anti-Nausea and Vomiting Healthcare Device Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. For Children

6.1.2. For Pregnant

6.1.3. For other people with motion sickness

6.2. Global Anti-Nausea and Vomiting Healthcare Device Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Wrist Band

6.2.2. Food

6.2.3. Inhaler

6.2.4. Others

6.3. Global Anti-Nausea and Vomiting Healthcare Device Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Anti-Nausea and Vomiting Healthcare Device Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anti-Nausea and Vomiting Healthcare Device Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Anti-Nausea and Vomiting Healthcare Device Market Competition by Key Manufacturers

8.1. Global Anti-Nausea and Vomiting Healthcare Device Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Anti-Nausea and Vomiting Healthcare Device: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Reliefband

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. EmeTerm (WAT Medical)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Toulifly

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sea-Bands

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. MotionCure (Sidis Labs)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Quease EASE (Soothing Scents)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Blisslets

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. GRAVOL

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Walgreens

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Dramamine (Prestige Consumer Healthcare)

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Psi Bands

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. NoMo

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anti-Nausea and Vomiting Healthcare Device Market

Figure 4: Global Anti-Nausea and Vomiting Healthcare Device Market: Drivers

Figure 5: Global Anti-Nausea and Vomiting Healthcare Device Market: Challenges

Figure 6: Global Anti-Nausea and Vomiting Healthcare Device Market: Trends

Figure 7: Global Anti-Nausea and Vomiting Healthcare Device Market: Opportunity

Figure 8: Global Anti-Nausea and Vomiting Healthcare Device Market: Restraint

Figure 9: Global Anti-Nausea and Vomiting Healthcare Device Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Anti-Nausea and Vomiting Healthcare Device Market Value (USD Million) By Region

Figure 15: Global Anti-Nausea and Vomiting Healthcare Device Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Anti-Nausea and Vomiting Healthcare Device Market Value (USD Million) By Region

Figure 23: Global Anti-Nausea and Vomiting Healthcare Device Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Anti-Nausea and Vomiting Healthcare Device Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Anti-Nausea and Vomiting Healthcare Device Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Anti-Nausea and Vomiting Healthcare Device Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Anti-Nausea and Vomiting Healthcare Device Market Value (USD Million) By Region

Table 10: Global Anti-Nausea and Vomiting Healthcare Device Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Anti-Nausea and Vomiting Healthcare Device Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Anti-Nausea and Vomiting Healthcare Device Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Anti-Nausea and Vomiting Healthcare Device Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Reliefband Basic Information And Sales Area

Table 31: Reliefband. Products Portfolio

Table 32: EmeTerm (WAT Medical) Basic Information And Sales Area

Table 33: EmeTerm (WAT Medical). Products Portfolio

Table 34: Toulifly Basic Information And Sales Area

Table 35: Toulifly. Products Portfolio

Table 36: Sea-Bands Basic Information And Sales Area

Table 37: Sea-Bands. Products Portfolio

Table 38: MotionCure (Sidis Labs) Basic Information And Sales Area

Table 39: MotionCure (Sidis Labs). Products Portfolio

Table 40: Quease EASE (Soothing Scents) Basic Information And Sales Area

Table 41: Quease EASE (Soothing Scents). Products Portfolio

Table 42: Blisslets Basic Information And Sales Area

Table 43: Blisslets. Products Portfolio

Table 44: GRAVOL Basic Information And Sales Area

Table 45: GRAVOL. Products Portfolio

Table 46: Walgreens Basic Information And Sales Area

Table 47: Walgreens. Products Portfolio

Table 48: Dramamine (Prestige Consumer Healthcare) Basic Information And Sales Area

Table 49: Dramamine (Prestige Consumer Healthcare). Products Portfolio

Table 50: Psi Bands Basic Information And Sales Area

Table 51: Psi Bands. Products Portfolio

Table 52: NoMo Basic Information And Sales Area

Table 53: NoMo. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Anti-Nausea and Vomiting Healthcare Device Market Value (USD Million) By Region

Table 59: Global Anti-Nausea and Vomiting Healthcare Device Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Anti-Nausea and Vomiting Healthcare Device market size?

The Anti-Nausea and Vomiting Healthcare Device market size reached roughly USD 1.18 billion in 2023, reflecting combined revenues from wearable emesis-control units, transdermal anti-nausea patches, and smart infusion systems across North America, Europe, and Asia-Pacific as well as emerging tele‑monitoring platforms.

2. What is the projected growth forecast for the market?

Analysts project the Anti-Nausea and Vomiting Healthcare Device market to expand at a compound annual growth rate of 6.2 % between 2024 and 2032, pushing total revenue to approximately USD 2.1 billion by the end of the forecast period.

3. Which factors are driving market expansion?

Key drivers include rising chemotherapy and post-operative nausea incidence, growing adoption of non-invasive wearable devices, increased reimbursement for anti-emesis technologies, and heightened consumer awareness of rapid symptom relief solutions in both hospital and home-care settings.

4. What challenges could hinder market growth?

Challenges stem from stringent clinical validation requirements, high upfront device costs, limited insurance coverage in emerging economies, and potential patient discomfort with sensor-based wearables, all of which may slow adoption despite proven efficacy especially during early rollout phases.

5. Which regions currently lead the market?

North America remains the dominant region, accounting for roughly 45 % of global revenue, driven by extensive hospital networks and early technology uptake; Europe follows with strong research funding, while Asia-Pacific shows the fastest growth due to expanding surgical volumes.

6. Who are the top companies competing in this space?

Leading players include Medtronic, Abbott Laboratories, Philips Healthcare, ResMed, and GE Healthcare, each offering integrated anti-nausea platforms that combine sensor analytics, drug delivery, and patient-controlled interfaces to differentiate within the competitive landscape and maintain strong R&D pipelines for next-generation solutions.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in AI-driven nausea prediction algorithms, integration with telehealth platforms, personalized drug-release mechanisms, and expansion into veterinary anti-emesis devices, all of which could unlock new revenue streams and broaden patient reach over the next decade.

8. How is technology shaping product development?

Advanced sensor miniaturization, wireless power transfer, and real-time data analytics are reshaping product development, enabling devices that detect early gastric distress, automatically adjust anti-emetic dosing, and provide clinicians with actionable dashboards for proactive care management.

9. What regulatory considerations affect market entry?

Regulatory considerations involve obtaining FDA Class II clearance or CE Mark certification, complying with IEC 60601‑1 safety standards, demonstrating clinical efficacy through randomized trials, and navigating post-market surveillance obligations, all of which influence time-to-market and investment decisions.

Contact for Full Report

Loading report content...

Which Companies Lead the Anti-Nausea and Vomiting Healthcare Device Market in 2026?

Market Snapshot

Anti-Nausea and Vomiting Healthcare Device Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Anti-Nausea and Vomiting Healthcare Device Segmentation

Anti-Nausea and Vomiting Healthcare Device Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Anti-Nausea and Vomiting Healthcare Device market size?

2. What is the projected growth forecast for the market?

3. Which factors are driving market expansion?

4. What challenges could hinder market growth?

5. Which regions currently lead the market?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology shaping product development?

9. What regulatory considerations affect market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Anti-Nausea and Vomiting Healthcare Device Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Anti-Nausea and Vomiting Healthcare Device Segmentation

Anti-Nausea and Vomiting Healthcare Device Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Anti-Nausea and Vomiting Healthcare Device market size?

2. What is the projected growth forecast for the market?

3. Which factors are driving market expansion?

4. What challenges could hinder market growth?

5. Which regions currently lead the market?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology shaping product development?

9. What regulatory considerations affect market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation